Respiratory Function in Patients With Post-tuberculosis Lung Impairment
Conditions:   Lung Diseases, Obstructive;   Pulmonary Rehabilitation;   Lung TB Intervention:   Procedure: Pulmonary Rehabilitation Sponsors:   Università degli Studi dell'Insubria;   Fondazione Salvatore Maugeri;   Azienda Ospedaliero Universitaria di Sassari;   Instituto Nacional de Enfermedades Respiratorias Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2019 Category: Research Source Type: clinical trials

Improving HIV/Tuberculosis Outcomes in Irkutsk
Conditions:   Tuberculosis;   HIV Infections;   Substance Use Intervention:   Sponsors:   University of Virginia;   National Institute on Drug Abuse (NIDA);   Scientific Center for Family Health and Human Reproduction Problems, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Conditions:   HIV Infections;   Tuberculosis Intervention:   Drug: Levonorgestrel Emergency Contraception (LNG EC) Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Improving HIV/Tuberculosis Outcomes in Irkutsk
Conditions:   Tuberculosis;   HIV Infections;   Substance Use Intervention:   Sponsors:   University of Virginia;   National Institute on Drug Abuse (NIDA);   Scientific Center for Family Health and Human Reproduction Problems, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Conditions:   HIV Infections;   Tuberculosis Intervention:   Drug: Levonorgestrel Emergency Contraception (LNG EC) Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Improving HIV/Tuberculosis Outcomes in Irkutsk
Conditions:   Tuberculosis;   HIV Infections;   Substance Use Intervention:   Sponsors:   University of Virginia;   National Institute on Drug Abuse (NIDA);   Scientific Center for Family Health and Human Reproduction Problems, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Conditions:   HIV Infections;   Tuberculosis Intervention:   Drug: Levonorgestrel Emergency Contraception (LNG EC) Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Improving HIV/Tuberculosis Outcomes in Irkutsk
Conditions:   Tuberculosis;   HIV Infections;   Substance Use Intervention:   Sponsors:   University of Virginia;   National Institute on Drug Abuse (NIDA);   Scientific Center for Family Health and Human Reproduction Problems, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Conditions:   HIV Infections;   Tuberculosis Intervention:   Drug: Levonorgestrel Emergency Contraception (LNG EC) Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Improving HIV/Tuberculosis Outcomes in Irkutsk
Conditions:   Tuberculosis;   HIV Infections;   Substance Use Intervention:   Sponsors:   University of Virginia;   National Institute on Drug Abuse (NIDA);   Scientific Center for Family Health and Human Reproduction Problems, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Conditions:   HIV Infections;   Tuberculosis Intervention:   Drug: Levonorgestrel Emergency Contraception (LNG EC) Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Improving HIV/Tuberculosis Outcomes in Irkutsk
Conditions:   Tuberculosis;   HIV Infections;   Substance Use Intervention:   Sponsors:   University of Virginia;   National Institute on Drug Abuse (NIDA);   Scientific Center for Family Health and Human Reproduction Problems, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Conditions:   HIV Infections;   Tuberculosis Intervention:   Drug: Levonorgestrel Emergency Contraception (LNG EC) Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Improving HIV/Tuberculosis Outcomes in Irkutsk
Conditions:   Tuberculosis;   HIV Infections;   Substance Use Intervention:   Sponsors:   University of Virginia;   National Institute on Drug Abuse (NIDA);   Scientific Center for Family Health and Human Reproduction Problems, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2019 Category: Research Source Type: clinical trials

Digital Health Promotion in Iringa, Tanzania
Conditions:   HIV Infections;   Tuberculosis;   Cysticercosis;   Tapeworm Pork Intervention:   Other: Digital health promotion intervention Sponsors:   University of Oslo;   National Institute for Medical Research, Tanzania;   Sokoine University of Agriculture;   Technische Universität München Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2019 Category: Research Source Type: clinical trials

A Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
Condition:   Tuberculosis Interventions:   Biological: Placebo;   Biological: ID93+GLA-SE Sponsors:   Quratis Inc.;   IDRI Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 16, 2019 Category: Research Source Type: clinical trials

A Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
Condition:   Tuberculosis Interventions:   Biological: Placebo;   Biological: ID93+GLA-SE Sponsor:   Quratis Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 16, 2019 Category: Research Source Type: clinical trials

A Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
Condition:   Tuberculosis Interventions:   Biological: Placebo;   Biological: ID93+GLA-SE Sponsors:   Quratis Inc.;   IDRI Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 16, 2019 Category: Research Source Type: clinical trials

A Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
Condition:   Tuberculosis Interventions:   Biological: Placebo;   Biological: ID93+GLA-SE Sponsor:   Quratis Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 16, 2019 Category: Research Source Type: clinical trials

A Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
Condition:   Tuberculosis Interventions:   Biological: Placebo;   Biological: ID93+GLA-SE Sponsors:   Quratis Inc.;   IDRI Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 16, 2019 Category: Research Source Type: clinical trials